Foresite Capital Fund IV, L.P. - 31 Jan 2025 SCHEDULE 13G Report for Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE)

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James Tananbaum
Security
Maze Therapeutics, Inc. Common Stock, par value $0.001
Symbol
MAZE
Shares outstanding
43,876,929 shares
Disclosed Ownership
2,457,108 shares
Ownership
5.6%
Form type
SCHEDULE 13G
Filing time
07 Feb 2025, 16:01:09 UTC
Date of event
31 Jan 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Quoteable Key Fact

"Foresite Capital Fund IV, L.P. disclosed 5.6% ownership in Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE) on 31 Jan 2025."

Quick Takeaways

  • Foresite Capital Fund IV, L.P. filed SCHEDULE 13G for Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE).
  • Disclosed ownership: 5.6%.
  • Date of event: 31 Jan 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 07 Feb 2025, 16:01.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 4.8% 2,111,917 2,111,917 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 4.8% 2,111,917 2,111,917 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 0.8% 345,191 345,191 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 0.8% 345,191 345,191 0 /s/ James Tananbaum James Tananbaum, Managing Member
James Tananbaum 5.6% 2,457,108 2,457,108 0 /s/ James Tananbaum James Tananbaum